Progression and regression of atherosclerosis in APOE3-Leiden transgenic mice: an immunohistochemical study.
Apolipoprotein E3-Leiden (APOE3-Leiden) transgenic mice develop hyperlipidemia and are highly susceptible to diet-induced atherosclerosis. We have studied the progression and regression of atherosclerosis using immunohistochemistry. Female transgenic mice were fed a moderate fat diet to study atherosclerosis over a longer time period. Fatty streaks arose in the intima and consisted of lipid filled macrophages which differed in origin. All macrophages expressed the macrophage scavenger receptor while two thirds expressed sialoadhesin and were positive for an antibody recognizing marginal zone macrophages (MOMA-1). All macrophages were negative for the scavenger receptor MARCO and 50% were positive for CD4. Small fatty streaks contained CD-3 positive T-lymphocytes which were for more than 70% CD4-positive. ICAM-1 was positive both in atherosclerotic and control mice. In early plaques, fibrosis was observed on the luminal and medial site of the foam cells while smooth muscle cells were only observed in the fibrous cap. To study regression, we used a high fat, high cholesterol diet to rapidly induce atherosclerosis (14 weeks). The animals were then fed normal chow. Subsequently, atherosclerosis was assayed over time (4, 8, 16 weeks). Cholesterol levels dropped in 4 weeks to control levels. The animals did not show a significantly decrease in plaque size over time. but the percentage macrophages was significantly smaller in the animals after 4 weeks. In conclusion, the APOE3-Leiden mouse is a useful model to study the progression and regression of atherosclerosis.
Gijbels
M J
MJ
Department of Cell Biology and Immunology, Vrije Universiteit, Amsterdam, The Netherlands. mg@ruly46.medfac.leidenuniv.nl
van der Cammen
M
M
van der Laan
L J
LJ
Emeis
J J
JJ
Havekes
L M
LM
Hofker
M H
MH
Kraal
G
G
D000818:Animals; D000911:Antibodies, Monoclonal; D001011:Aorta / Q000737:chemistry / Q000473:pathology*; D053318:Apolipoprotein E3; D001057:Apolipoproteins E / Q000235:genetics*; D001161:Arteriosclerosis / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D015704:CD4 Antigens / Q000032:analysis; D015815:Cell Adhesion Molecules / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D018450:Disease Progression; D004730:Endothelium, Vascular / Q000473:pathology; D005260:Female; D007150:Immunohistochemistry; D018799:Intercellular Adhesion Molecule-1 / Q000032:analysis; D008264:Macrophages / Q000145:classification / Q000473:pathology; D008562:Membrane Glycoproteins / Q000032:analysis; D051379:Mice; D008822:Mice, Transgenic; D011971:Receptors, Immunologic / Q000032:analysis; D051116:Receptors, Scavenger; D063267:Sialic Acid Binding Ig-like Lectin 1; D013601:T-Lymphocytes / Q000145:classification / Q000473:pathology; D014280:Triglycerides / Q000097:blood
D000911:Antibodies, Monoclonal; D053318:Apolipoprotein E3; D001057:Apolipoproteins E; D015704:CD4 Antigens; D015815:Cell Adhesion Molecules; D002791:Cholesterol, Dietary; D008562:Membrane Glycoproteins; D011971:Receptors, Immunologic; D051116:Receptors, Scavenger; D063267:Sialic Acid Binding Ig-like Lectin 1; C571167:Siglec1 protein, mouse; D014280:Triglycerides; C052720:apolipoprotein E3 (Leidein); D018799:Intercellular Adhesion Molecule-1; D002784:Cholesterol